The efficacy of intravitreal ranibizumab injection for idiopathic choroidal neovascularization with different courses

Abstract

Objective To observe the efficacy of intravitreal injection of ranibizumab for idiopathic choroidal neovascularization with different courses. Methods Clinical retrospective study. Fifty-four eyes of 54 patients with idiopathic choroidal neovascularization (ICNV) who received intravitreal ranibizumab injection were divided into early group, 30 cases, duration of disease ≤3 months and middle group, 24 cases, duration of disease 4-6 months. The follow-up time was 12 months.The visual acuity, intraocular pressure and central macular thickness (CMT) and before and after treatment were observed and compared. Results The difference of visual acuity and CMT at 1, 3, 6 and 12 months after treatment were statistically significant between before and after treatment (P<0.05). The difference of visual acuity and CMT between the two groups at each follow-up time were statistically significant (P<0.05). At the last follow-up, the mean time of injections in the early group was significantly lower than that in the middle group (t=2.668, P=0.009). FFA showed the difference was statistically significant in the leakage of the lesion between the two groups (χ2=4.260, P=0.004). No significant eye and systemic complication occurred during the follow-up period. Conclusion Intravitreal ranibizumab injection can improve visual acuity and reduce macular edema, early treatment can reduce the times of injection, more effectively control CNV lesion leakage. Key words: Ranibizumab, intravitreal injection; Efficacy; Neovascularization, choroidal